The Nomination Committee’s Proposals to the Annual General Meeting in Karo Bio AB (publ)

Regulatory News:

Karo Bio (STO:KARO)

The Nomination Committee of Karo Bio AB (publ) has informed the company of its proposals to the annual general meeting 2015.

Prior to the annual general meeting 2015, the Nomination Committee has consisted of Anders Lönner (chairman), chairman of the board, representing own holdings, Göran Wessman, representing own holdings (Protem Wessman AB), Johan Paulsson, representing own holdings (JPMP i Visby AB), Leif Edlund, representing Johan Edlund and Per-Anders Johansson, representing own holdings (Nomic AB). Anders Lönner has been elected chairman of the Nomination Committee.

The nomination committee proposes re-election of the board members Anders Lönner, Thomas Hedner, Göran Wessman, Per-Anders Johansson and new election of Jean Lycke. Sibylle Lenz and Christer Fåhraeus have declined re-election. Anders Lönner is proposed to be elected chairman of the board.

Jean Lycke (born 1964), has great experience of business development within the pharmaceutical industry. Jean Lycke is, among other things, chairman of the board of Tanomed AB, board member and managing director of Emerentia Gruppen AB, board member of BioResonator Good Eye AB and Santax Nordic A/S. Jean Lycke holds presently no shares in the company.

The Nomination Committee is of the opinion that the remuneration to the board should remain unchanged and be paid by SEK 420,000 to the chairman and SEK 150,000 to each of the other directors.

The Nomination Committee further proposes re-election of the accounting firm PricewaterhouseCoopers AB and that remuneration to the auditor be paid as per approved invoice.

Advokat Madeleine Rydberger is proposed to be chairman of the meeting.

The Nomination Committee’s reasoned statement on its proposals to the annual general meeting will be published on the company’s website as soon as it is received by the company.

About Karo Bio

Karo Bio is a development company focused on broadening its operations to include projects and products closer to market. Karo Bio has several projects approaching clinical phase. Karo Bio is based in Huddinge, Sweden and is listed on Nasdaq Stockholm.

Karo Bio publishes this information according to the Swedish Securities Market Act. The information was submitted for publication on 23 April 2015, at 8.30 a.m. CET.

This press release is also available at www.karobio.se and www.newsroom.cision.com

This information was brought to you by Cision http://news.cision.com